{
    "id": 29477,
    "fullName": "ANKRD1 over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "ANKRD1 over exp indicates an over expression of the Ankrd1 protein and/or mRNA. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 27063,
        "geneSymbol": "ANKRD1",
        "terms": [
            "ANKRD1",
            "ALRP",
            "bA320F15.2",
            "C-193",
            "CARP",
            "CVARP",
            "MCARP"
        ]
    },
    "variant": "over exp",
    "createDate": "02/26/2019",
    "updateDate": "02/26/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 16142,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of ANKRD1 was identified following acquired resistance to Gilotrif (afatinib) in culture in two lung adenocarcinoma cell lines harboring EGFR exon 19 deletions, and these cells were re-sensitized by ANKRD1 knockdown (PMID: 30291293).",
            "molecularProfile": {
                "id": 31511,
                "profileName": "ANKRD1 over exp EGFR exon 19 del"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14283,
                    "pubMedId": 30291293,
                    "title": "Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30291293"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16147,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gleevec (imatinib) treatment restored sensitivity to Tagrisso (osimertinib) treatment in two lung adenocarcinoma cell lines harboring an EGFR exon 19 deletion and overexpressing ANKRD1 in culture (PMID: 30291293).",
            "molecularProfile": {
                "id": 31511,
                "profileName": "ANKRD1 over exp EGFR exon 19 del"
            },
            "therapy": {
                "id": 7909,
                "therapyName": "Imatinib + Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14283,
                    "pubMedId": 30291293,
                    "title": "Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30291293"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16146,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gleevec (imatinib) restored sensitivity of Gilotrif (afatinib) treatment in two lung adenocarcinoma cell lines each harboring an EGFR exon 19 deletion and overexpressing ANKRD1 in culture (PMID: 30291293).",
            "molecularProfile": {
                "id": 31511,
                "profileName": "ANKRD1 over exp EGFR exon 19 del"
            },
            "therapy": {
                "id": 7908,
                "therapyName": "Afatinib + Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14283,
                    "pubMedId": 30291293,
                    "title": "Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30291293"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16144,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of ANKRD1 was identified following acquired resistance to Tagrisso (osimertinib) in culture in two lung adenocarcinoma cell lines each harboring an EGFR exon 19 deletion, and one of these two cell lines was re-sensitized by ANKRD1 knockdown (PMID: 30291293).",
            "molecularProfile": {
                "id": 31511,
                "profileName": "ANKRD1 over exp EGFR exon 19 del"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14283,
                    "pubMedId": 30291293,
                    "title": "Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30291293"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16145,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gleevec (imatinib) treatment resulted in decreased Ankrd1 expression and induction of apoptosis in two Gilotrif (afatinib)-resistant and two Tagrisso (osimertinib)- resistant lung adenocarcinoma cell lines harboring an EGFR exon 19 deletion and overexpressing ANKRD1 in culture (PMID: 30291293).",
            "molecularProfile": {
                "id": 31511,
                "profileName": "ANKRD1 over exp EGFR exon 19 del"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14283,
                    "pubMedId": 30291293,
                    "title": "Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30291293"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 31510,
            "profileName": "ANKRD1 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31511,
            "profileName": "ANKRD1 over exp EGFR exon 19 del",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}